U.S. Markets open in 6 hrs 32 mins

DBV Technologies S.A. (DBV.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
8.80-0.01 (-0.11%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.81
Open8.67
BidN/A x N/A
AskN/A x N/A
Day's Range8.55 - 8.86
52 Week Range2.35 - 13.69
Volume195,645
Avg. Volume238,304
Market Cap483.08M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateOct 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights08/31/202155,011,687 Total gross of voting rights: 55,011,687 Total net* of voting rights: 54,963,687 * Total net = total number of voting rights attached to shares – shares with

  • GlobeNewswire

    DBV Technologies to Participate at Upcoming Investor Conferences

    Montrouge, France, August 31, 2021 DBV Technologies to Participate at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that DBV Technologies’ senior management team will participate in upcoming virtual investor conferences in September. Goldman Sachs Eleventh Annual Biotech Symposium Company management will participate in virtual investor meetings on September 7, 2021. Citi

  • GlobeNewswire

    Beyond Air® Announces CFO Transition

    GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 20